論文・技術情報追加のお知らせ

1. Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database.

脳卒中患者におけるアルテプラーゼは浮腫リスクが高い

対象DB：FAERS

2. Isotretinoin and Suicide: Data Mining of the United States Food and Drug Administration Adverse Event Reporting System Database.

イソトレチノインと自殺関連の副作用

対象DB：FAERS

3. Ginkgo biloba Extract Safety: Insights from a Real-world Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) Events.

イチョウ葉抽出物は有害事象のリスクがある

対象DB：FAERS

4. Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis.

アトルバスタチンは神経系の有害事象リスクが高い可能性

対象DB：FAERS

5. Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases.

トルバプタンに関連する肝障害は重篤で、年齢による発症時間の差がある

対象DB：FAERS,JADER

6. Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC).

HNSCC治療において、ニボルマブが最も安全なPD-1/PD-L1阻害薬

対象DB：FAERS

7. Drug-induced noninfectious myocarditis: a disproportionality analysis of the FAERS database.

非感染性心筋炎に関連する薬剤が特定された

対象DB：FAERS

8. Adverse events associated with Stiripentol in children aged 0-17 years: An analysis of a real-world pharmacovigilance database.

小児のスチリペントール使用で神経系などの有害事象が確認され、年齢・性別差も示唆された

対象DB：FAERS,VigiBase

9. Effects of age, sex, daily dose, comorbidity and co-medication on venlafaxine-associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database.

ベンラファキシン使用で心血管系有害事象が増加、高齢者は注意

対象DB：FAERS

10. Comprehensive evaluation of leuprorelin-associated adverse events: insights from FDA adverse event reporting system.

リュープロレリンの使用でまれな副作用が報告され、さらなる調査が必要

対象DB：FAERS

11. Psychiatric disorders associated with fluoroquinolones: a pharmacovigilance analysis of the FDA adverse event reporting system database.

フルオロキノロン系抗菌薬は精神障害の副作用リスクがあり、特にうつやせん妄に注意

対象DB：FAERS

12. Hepatotoxicity of antipsychotics: an exploratory pharmacoepidemiologic and pharmacodynamic study integrating FAERS data and in vitro receptor-binding affinities.

抗精神病薬は肝障害のリスクがあり、特に女性に多く、セロトニン受容体との関係が示唆される

対象DB：FAERS

13. A real-world pharmacovigilance study of FDA adverse event reporting system events for Lutetium-177-PSMA-617.

177Lu-PSMA-617は貧血や血小板減少などの副作用リスクあり

対象DB：FAERS

14. Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system.

父親の薬物曝露が妊娠や子供の健康に影響するリスクあり

対象DB：FAERS

15. Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system.

ICI関連の水疱性類天疱瘡は男性や65歳以上に多く、皮膚癌患者でリスク増

対象DB：FAERS

16. Drug-associated glaucoma: A real-world study based on the Food and Drug Administration adverse event reporting system database.

数百の薬剤が緑内障に関連し、特に女性や高齢者に多く見られた

対象DB：FAERS

17. Real-World Data Mining for Signal Detection of Antipsychotics-Associated Adverse Events Using the Korea Adverse Event Reporting System (KAERS) Database.

抗精神病薬は運動障害や代謝異常を引き起こす可能性がある

対象DB：FAERS,KAERS

18. Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System.

多発性骨髄腫の抗体治療は神経精神的有害事象がある

対象DB：FAERS

19. Exploration of the potential association between newer antiseizure medications and arrhythmias: Integrating pharmacovigilance and bioinformatics evidence.

新しい抗てんかん薬は不整脈リスクの可能性

対象DB：FAERS

20. Photosensitivity From Avapritinib: Pharamacovigilance Analysis.

アバプリチニブは光過敏症のリスクあり

対象DB：FAERS

21. Association between Polypharmacy and Adverse Events in Patients with Alzheimer's Disease: An Analysis of the Japanese Adverse Drug Event Report Database (JADER).

アルツハイマー治療は多剤併用で副作用増加

対象DB：JADER

22. Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database.

インクライシランは筋痛等の副作用リスクあり

対象DB：EudraVigilance

23. Drug-Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database.

SSRIの薬物相互作用は少数だが重篤なリスクあり

対象DB：EudraVigilance

24. Safety Profiles Related to Dosing Errors of Rapid-Acting Insulin Analogs: A Comparative Analysis Using the EudraVigilance Database.

RAIAで少数の投与ミスが発生し、重症例多。精密投与が重要

対象DB：EudraVigilance

25. Dementia severity and advanced pressure injury procedures and prognosis: A nationwide study in Japan.

重度認知症高齢者は褥瘡治療・回復が遅れがち

対象DB：DPC

26. Chronic hepatitis B costs and healthcare resource utilization in a Japanese patient population: a retrospective cross-sectional analysis.

日本での慢性B型肝炎は合併症で医療費が増加

対象DB：MDV

27. Is alcohol use disorder associated with higher rates of depression and anxiety among people with new onset type 2 diabetes? A cohort study using linked primary care data in England.

T2DM患者でAUD併発時、うつと不安リスクが倍増

対象DB：CPRD

28. Recommendations to promote equity, diversity and inclusion in decentralized clinical trials.

デジタル活用の臨床試験で公平な参加促進が課題

対象DB：CPRD

29. The association between drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a case-control study.

ペニシリン系抗生物質や糖尿病薬でBPリスク増加

対象DB：CPRD

30. Single-inhaler triple versus LABA-ICS therapy for COPD: Comparative safety in real-world clinical practice.

COPDの3剤併用療法で心血管イベントが増加傾向、特に最初の4ヶ月に顕著

対象DB：CPRD